{
  "schemaVersion": "2.1",
  "datasetVersion": "2026-09-11.1",
  "generatedAt": "2026-09-11",
  "reviewStatus": "Editorial source review is complete. This edition has not been independently medically reviewed.",
  "editorialBoundary": "Source-checked educational summaries. Topics require evidence and editorial review. This dataset is not a personal treatment plan.",
  "citation": "When you cite a record, include The Peptide Field, its canonicalPath, this dataset version, and every source used for the claim.",
  "reuse": "This endpoint grants no additional reuse license. Keep the verdict, scope, evidence basis, review date, and source links together. Do not present a record as medical advice or medical review.",
  "changeLogPath": "/corrections#correction-ledger",
  "contactPath": "/corrections",
  "dataset": "peptide-evidence-checker-record",
  "canonicalPath": "/peptides/semaglutide",
  "canonicalUrl": "https://thepeptidefield.com/peptides/semaglutide",
  "record": {
    "slug": "semaglutide",
    "name": "Semaglutide",
    "className": "GLP-1 receptor agonist",
    "sequenceLabel": "31 amino acids · modified peptide",
    "tier": "Established",
    "statusLine": "Yes. Some semaglutide prescription products are FDA-approved for specific uses",
    "profile": {
      "humanOutcomes": {
        "level": "Strong",
        "note": "Large studies support the approved uses listed on each product label."
      },
      "humanPharmacology": {
        "level": "Strong",
        "note": "Studies have measured how approved products act in the body and how the body processes them."
      },
      "safetyKnowledge": {
        "level": "Strong",
        "note": "Current product labels list known risks, warnings, and when each product should not be used."
      },
      "productCertainty": {
        "level": "Strong",
        "note": "High for an authentic approved product. This evidence does not transfer to every compounded version."
      }
    },
    "oneLine": "This review covers Ozempic, Rybelsus, Wegovy, and the Wegovy HD strength. Their forms, approved uses, and labels differ.",
    "reviewedAt": "August 30, 2026",
    "whatItIs": "Semaglutide is a modified peptide. It is the active ingredient in several prescription medicines. The name alone does not tell you the product, form, approved use, or safety rules. FDA approval and study results belong to the exact product and its current label.",
    "whatWeKnow": "FDA-reviewed semaglutide products have approved uses and official labels. Each label says who the product is for, its warnings, side effects, and directions. Read the current label for the exact product. Do not rely on the ingredient name alone.",
    "whatWeDoNotKnow": "A shared ingredient name does not make two products the same. Evidence from an approved product does not automatically apply to an unapproved, compounded, counterfeit, or research-labeled product. The name alone does not prove equal quality, safety, or results.",
    "safetyBoundary": "This guide does not recommend a product, say who can use it, or give dosing instructions. A licensed clinician must use the current label and a person's medical history to make treatment decisions.",
    "claims": [
      {
        "claim": "“Semaglutide is FDA-approved.”",
        "verdict": "Supported with scope",
        "explanation": "FDA approves a specific product for specific uses. The current Wegovy label lists different forms, groups of people, uses, and limits.",
        "category": "Approval and status",
        "evidenceBasis": "Regulatory or product record",
        "scope": "The exact semaglutide products, forms, people, and uses named in current FDA labels.",
        "sourceUrls": [
          "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf",
          "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051s024%2Cs028s029lbl.pdf",
          "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf"
        ]
      },
      {
        "claim": "“Compounded semaglutide is the same as an approved product.”",
        "verdict": "Misleading",
        "explanation": "FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing.",
        "category": "Product equivalence",
        "evidenceBasis": "Regulatory or product record",
        "scope": "Compounded or otherwise unapproved semaglutide products compared with FDA-approved products.",
        "sourceUrls": [
          "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"
        ]
      },
      {
        "claim": "“A result in one population proves the same benefit for everyone.”",
        "verdict": "Not established",
        "explanation": "A study supports only the people, product form, dose, length, approved use, and result that it tested.",
        "category": "Clinical outcomes",
        "evidenceBasis": "Randomized human outcomes",
        "scope": "The people, product forms, measured results, and study lengths described in the cited product record.",
        "sourceUrls": [
          "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf"
        ]
      }
    ],
    "sources": [
      {
        "label": "OZEMPIC (semaglutide) prescribing information, revised 05/2026",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf",
        "kind": "Drug label",
        "accessedAt": "2026-08-30",
        "year": 2026
      },
      {
        "label": "RYBELSUS (semaglutide) prescribing information, revised 10/2025",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051s024%2Cs028s029lbl.pdf",
        "kind": "Drug label",
        "accessedAt": "2026-08-30",
        "year": 2025
      },
      {
        "label": "WEGOVY (semaglutide) prescribing information, revised 06/2026",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf",
        "kind": "Drug label",
        "accessedAt": "2026-08-30",
        "year": 2026
      },
      {
        "label": "FDA’s concerns with unapproved GLP-1 drugs used for weight loss",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss",
        "kind": "Regulatory",
        "accessedAt": "2026-08-30",
        "year": 2026
      },
      {
        "label": "Drug approvals and databases",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases",
        "kind": "Regulatory",
        "accessedAt": "2026-08-30",
        "year": 2026
      },
      {
        "label": "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide",
        "publisher": "PubMed · Journal of Medicinal Chemistry",
        "url": "https://pubmed.ncbi.nlm.nih.gov/26308095/",
        "kind": "Preclinical",
        "year": 2015,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "FDA substance record: semaglutide identity (not an approval record)",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://precision.fda.gov/ginas/app/ui/substances/6008afca-8b87-4b98-9c27-3a6878147556",
        "kind": "Reference",
        "year": 2026,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "2026 Monitoring Program",
        "publisher": "World Anti-Doping Agency",
        "url": "https://www.wada-ama.org/sites/default/files/2025-09/2026_list_monitoring_program_en_final_clean_september_2025.pdf",
        "kind": "Anti-doping",
        "year": 2026,
        "accessedAt": "2026-08-30"
      }
    ],
    "aliases": [
      "Ozempic",
      "Wegovy",
      "Wegovy HD",
      "Rybelsus",
      "GLP-1 analog"
    ],
    "family": "Metabolic peptide medicines",
    "evidenceContext": "Approved human outcomes",
    "productContext": "Ozempic, Rybelsus, and Wegovy are distinct approved products. Wegovy HD is a higher-dose Wegovy injection strength. Evidence for one product or form does not automatically apply to another.",
    "approvedProducts": [
      "Ozempic",
      "Wegovy",
      "Wegovy HD",
      "Rybelsus"
    ],
    "productRecords": [
      {
        "name": "Ozempic",
        "formulation": "Injection",
        "route": "Injection under the skin",
        "indicationScope": "Adults with type 2 diabetes for blood-sugar control. The label also covers heart-risk reduction in adults with type 2 diabetes and established heart disease. It covers kidney-risk reduction in adults with type 2 diabetes and chronic kidney disease.",
        "labelUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf",
        "labelRevision": "May 2026"
      },
      {
        "name": "Rybelsus",
        "formulation": "Tablet",
        "route": "Tablet by mouth",
        "indicationScope": "Adults with type 2 diabetes for blood-sugar control. The label also covers heart-risk reduction in adults with type 2 diabetes who are at high risk. It is not approved for weight management.",
        "labelUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213051s024%2Cs028s029lbl.pdf",
        "labelRevision": "October 2025"
      },
      {
        "name": "Wegovy",
        "formulation": "Injection and tablet formulations",
        "route": "Injection under the skin or tablet by mouth",
        "indicationScope": "The injection label covers weight management in defined adults and children age 12 and older. It also covers heart-risk reduction in defined adults. MASH is a liver disease. When used with a reduced-calorie diet and increased physical activity, the injection label covers MASH in adults without cirrhosis who have moderate to advanced liver scarring (F2–F3). The tablet label covers adult weight management and heart-risk reduction.",
        "labelUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf",
        "labelRevision": "June 2026"
      },
      {
        "name": "Wegovy HD",
        "formulation": "7.2 mg injection strength",
        "route": "Injection under the skin",
        "indicationScope": "The 7.2 mg Wegovy injection strength for the adult weight-management group named in the label.",
        "labelUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf",
        "labelRevision": "June 2026"
      }
    ],
    "indications": [
      "Ozempic: blood-sugar control for adults with type 2 diabetes",
      "Ozempic: heart-risk reduction for adults with type 2 diabetes and established heart disease",
      "Ozempic: kidney- and heart-risk reduction for adults with type 2 diabetes and chronic kidney disease",
      "Rybelsus: blood-sugar control for adults with type 2 diabetes",
      "Rybelsus: heart-risk reduction for adults with type 2 diabetes who are at high risk",
      "Wegovy injection: weight management for the adults and children age 12 and older named in the label",
      "Wegovy tablets: weight management for the adults named in the label",
      "Wegovy injection and tablets: heart-risk reduction for the adults named in the label",
      "Wegovy injection, with a reduced-calorie diet and increased physical activity: MASH in adults without cirrhosis who have moderate to advanced liver scarring (F2–F3). FDA granted accelerated approval after improvements in MASH and liver scarring. Continued approval can depend on a later study that confirms benefit."
    ],
    "reviewedAtISO": "2026-08-30",
    "reviewHistory": [
      {
        "date": "2026-08-30",
        "note": "Checked current Ozempic, Rybelsus, and Wegovy labels. Added the Wegovy injection use for MASH, kept each form's limits, and checked the 2026 sports monitoring record."
      },
      {
        "date": "2026-08-01",
        "note": "Revalidated the semaglutide approval claim against the current Wegovy label and retained product-, formulation-, population-, and indication-specific scope."
      },
      {
        "date": "2026-07-23",
        "note": "Expanded product, claim, and source provenance fields."
      }
    ],
    "antiDoping": null,
    "antiDopingReview": {
      "status": "No prohibition identified",
      "detail": "No ban was identified in the checked 2026 WADA record. WADA monitors markers of semaglutide in and out of competition. Monitoring is not the same as a ban. Check the current list and your sport's rules.",
      "sourceUrl": "https://www.wada-ama.org/sites/default/files/2025-09/2026_list_monitoring_program_en_final_clean_september_2025.pdf",
      "reviewedAtISO": "2026-08-30"
    },
    "relatedSlugs": [
      "liraglutide",
      "tirzepatide",
      "retatrutide"
    ]
  }
}